MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
Status:
Completed
Trial end date:
2020-03-17
Target enrollment:
Participant gender:
Summary
MET-2 clinical study is an Open label, single center, multiple dose pilot study of 19
patients. The study is designed to measure the resolution of diarrhea as well as the
feasibility of administration and safety of MET-2 for the treatment of recurrent CDI in
patients who have experienced at least two prior episodes of CDI and have developed
recurrence after having completed standard-of care oral antibiotic therapy to treat CDI.